OOIR: Observatory of International Research

Papers

(The median citation count of Thoracic Cancer is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Curcumin induces ferroptosis in non‐small‐cell lung cancer via activating autophagy	98
Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis	85
Quercetin induces pro‐apoptotic autophagy via SIRT1/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro	71
A meta‐analysis of contrast‐enhanced spectral mammography versus MRI in the diagnosis of breast cancer	48
Circ‐RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR‐140‐5p	45
LncRNA HOTAIR enhances breast cancer radioresistance through facilitating HSPA1A expression via sequestering miR‐449b‐5p	42
Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients	41
Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients	40
Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series an	39
Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertions	38
Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR‐193a/HMGB1/PI3K/AKT axis	37
Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients	36
CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)	36
Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040	34
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events	33
circ_0007385 served as competing endogenous RNA for miR‐519d‐3p to suppress malignant behaviors and cisplatin resistance of non‐small cell lung cancer cells	32
Impact of COVID‐19 pandemic on lung cancer treatment scheduling	31
Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review	31
Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer	30
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non‐small cell lung cancer treated with anti‐PD‐1 antibody	29
Propofol suppresses lung cancer tumorigenesis by modulating the circ‐ERBB2/miR‐7‐5p/FOXM1 axis	28
Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer	27
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells	27
Circ_0038467 regulates lipopolysaccharide‐induced inflammatory injury in human bronchial epithelial cells through sponging miR‐338‐3p	27
miR‐21‐5p/SMAD7 axis promotes the progress of lung cancer	27

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study	26
Serum exosomal miR‐1269a serves as a diagnostic marker and plays an oncogenic role in non‐small cell lung cancer	25
Circ_0072088 promotes the development of non‐small cell lung cancer via the miR‐377‐5p/NOVA2 axis	24
Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer	24
Tumor‐associated macrophages: An important player in breast cancer progression	24
Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study	24
Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors	24
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real‐world efficacy and safety in advanced/recurrent non‐small cell lung carcinoma	23
MiR‐429 suppresses proliferation and invasion of breast cancer via inhibiting the Wnt/β‐catenin signaling pathway	22
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients	22
Surgical effect and prognostic factors of myasthenia gravis with thymomas	22
KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma	22
Global burden of thyroid cancer and its attributable risk factors in 204 countries and territories from 1990 to 2019	22
CAR‐T cell therapy for lung cancer: Potential and perspective	22
Postoperative short‐term outcomes of minimally invasive versus open esophagectomy for patients with esophageal cancer: An updated systematic review and meta‐analysis	21
Adverse impact of bone metastases on clinical outcomes of patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors	21
Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer	21
LncRNASGMS1‐AS1 regulates lung adenocarcinoma cell proliferation, migration, invasion, and EMT progression via miR‐106a‐5p/MYLI9 axis	21
Identifying sarcopenia in advanced non‐small cell lung cancer patients using skeletal muscle CT radiomics and machine learning	21
Downregulation of m⁶A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer	20
Tumor‐educated platelet SNORD55 as a potential biomarker for the early diagnosis of non‐small cell lung cancer	20
Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer	20
Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR‐mutation non‐small cell lung cancer: A phase II single‐arm prospective clinical trial	20
Plasma miR‐1247‐5p, miR‐301b‐3p and miR‐105‐5p as potential biomarkers for early diagnosis of non‐small cell lung cancer	20
GPX8 promotes migration and invasion by regulating epithelial characteristics in non‐small cell lung cancer	20
Robot‐assisted thoracic surgery versus video‐assisted thoracic surgery for treatment of patients with thymoma: A systematic review and meta‐analysis	19
PIWI‐interacting RNAs are aberrantly expressed and may serve as novel biomarkers for diagnosis of lung adenocarcinoma	19
Clinical utility of the C‐reactive protein:albumin ratio in non‐small cell lung cancer patients treated with nivolumab	19
Exosomal miR‐3180‐3p inhibits proliferation and metastasis of non‐small cell lung cancer by downregulating FOXP4	19
The value of navigation bronchoscopy in the diagnosis of peripheral pulmonary lesions: A meta‐analysis	19
miR‐874 directly targets AQP3 to inhibit cell proliferation, mobility and EMT in non‐small cell lung cancer	19
Clinical implication of minimal presence of solid or micropapillary subtype in early‐stage lung adenocarcinoma	19
Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review	19
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China	18
microRNA‐100 functions as a tumor suppressor in non‐small cell lung cancer via regulating epithelial‐mesenchymal transition and Wnt/β‐catenin by targeting HOXA1	18
Tumor‐associated macrophages (TAMs)‐derived osteopontin (OPN) upregulates PD‐L1 expression and predicts poor prognosis in non‐small cell lung cancer (NSCLC)	18
Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer	18
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice	18
A novel lncRNA‐miRNA‐mRNA competing endogenous RNA regulatory network in lung adenocarcinoma and kidney renal papillary cell carcinoma	18
tRNA‐derived fragments: tRF‐Gly‐CCC‐046, tRF‐Tyr‐GTA‐010 and tRF‐Pro‐TGG‐001 as novel diagnostic biomarkers for breast cancer	18
MicroRNA‐125b as a tumor suppressor by targeting MMP11 in breast cancer	18
Role of endothelin receptor type B (EDNRB) in lung adenocarcinoma	18
Spread through air spaces (STAS) in invasive mucinous adenocarcinoma of the lung: Incidence, prognostic impact, and prediction based on clinicoradiologic factors	18
LncRNA LINC00460: Function and mechanism in human cancer	18
Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis	17
Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis	17
Predictors of survival among Japanese patients receiving first‐line chemoimmunotherapy for advanced non‐small cell lung cancer	17
Cantharidin‐loaded functional mesoporous titanium peroxide nanoparticles for non‐small cell lung cancer targeted chemotherapy combined with high effective photodynamic therapy	17
Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database	17
miR‐15b enhances the proliferation and migration of lung adenocarcinoma by targeting BCL2	17

Novel long non‐coding RNA LINC02323 promotes epithelial‐mesenchymal transition and metastasis via sponging miR‐1343‐3p in lung adenocarcinoma	17
Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation	16
Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients	16
Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy	16
LncRNA FAM83A‐AS1 promotes lung adenocarcinoma progression by enhancing the pre‐mRNA stability of FAM83A	16
Assessment of anxiety and depression in patients with incidental pulmonary nodules and analysis of its related impact factors	16
Comprehensive genomic profiling of Brazilian non‐small cell lung cancer patients (GBOT 0118/LACOG0418)	16
Prognostic value of the geriatric nutritional risk index among patients with previously treated advanced non‐small cell lung cancer who subsequently underwent immunotherapy	16
Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients	16
Association between pretreatment neutrophil‐to‐lymphocyte ratio and immune‐related adverse events due to immune checkpoint inhibitors in patients with non‐small cell lung cancer	16
Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug‐eluting beads in patients with stage II–IV lung cancer: A prospective cohort study	16
Safety and effectiveness of pirfenidone combined with carboplatin‐based chemotherapy in patients with idiopathic pulmonary fibrosis and non‐small cell lung cancer: A retrospective cohort study	16
Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer	16
Identification of a novel anoikis‐related gene signature to predict prognosis and tumor microenvironment in lung adenocarcinoma	16
Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer	15
Overexpression of hsa_circ_0008274 inhibited the progression of lung adenocarcinoma by regulating HMGA2 via sponging miR‐578	15
Identification of small proline‐rich protein 1B (SPRR1B) as a prognostically predictive biomarker for lung adenocarcinoma by integrative bioinformatic analysis	15
Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID‐19 epidemic	15
CAPN1 promotes malignant behavior and erlotinib resistance mediated by phosphorylation of c‐Met and PIK3R2via degrading PTPN1 in lung adenocarcinoma	15
Characteristics of surgically resected non‐small cell lung cancer patients with post‐recurrence cure	15
Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR‐1271‐5p and upregulating FRS2	15
Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer	15
Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy	15
Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors	15
MiR‐133a acts as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF‐β/Smad3 signaling pathway	15
Bronchobiliary fistula after ablation of hepatocellular carcinoma adjacent to the diaphragm: Case report and literature review	15
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG‐LU16‐07	15
Propofol suppresses hypoxia‐induced esophageal cancer cell migration, invasion, and EMT through regulating lncRNA TMPO‐AS1/miR‐498 axis	14
LncRNA LINC00511 plays an oncogenic role in lung adenocarcinoma by regulating PKM2 expression via sponging miR‐625‐5p	14
Diagnostic yield of additional conventional transbronchial lung biopsy following radial endobronchial ultrasound lung biopsy for peripheral pulmonary lesions	14
Long non‐coding RNA HCG11 sponging miR‐522‐3p inhibits the tumorigenesis of non‐small cell lung cancer by upregulating SOCS5	14
Comparative study on preoperative localization techniques using microcoil and hookwire by propensity score matching	14
Impacts of post‐radiotherapy lymphocyte count on progression‐free and overall survival in patients with stage III lung cancer	14
Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria	14
Differential diagnosis of lung cancer and benign lung lesion using salivary metabolites: A preliminary study	14
Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: A single‐institute experience of 10 cases	14
Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance	14
Invasive mucinous adenocarcinoma of the lung: Serial CT findings, clinical features, and treatment and survival outcomes	14
Clinical characteristics and risk factors for in‐hospital mortality of lung cancer patients with COVID‐19: A multicenter, retrospective, cohort study	14
Electromagnetic navigation bronchoscopic localization versus percutaneous CT‐guided localization for thoracoscopic resection of small pulmonary nodules	14
MiR‐205‐5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer	14
Hsa_circRNA_0000518 facilitates breast cancer development via regulation of the miR‐326/FGFR1 axis	14
Immunotherapy as second‐line treatment and beyond for non‐small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real‐world retrospective anal	14
Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature	14
ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer	13
A nurse‐driven enhanced recovery after surgery (ERAS) nursing program for geriatric patients following lung surgery	13
Exosome miR‐27a‐3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma	13
LINC00662 promotes cell viability and metastasis in esophageal squamous cell carcinoma by sponging miR‐340‐5p and upregulating HOXB2	13
SHR‐1316, an anti‐PD‐L1 antibody, plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study	13
Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection	13
Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone	13
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs	13
Factors related to rapid progression of non‐small cell lung cancer in Chinese patients treated using single‐agent immune checkpoint inhibitor treatment	13
Real‐world efficacy of atezolizumab in non‐small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti‐PD‐1 antibody	13
Long non‐coding RNA SNHG6 promotes the growth and invasion of non‐small cell lung cancer by downregulating miR‐101‐3p	13
Aspirin‐targeted PD‐L1 in lung cancer growth inhibition	13
Short‐term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm	13
Long‐term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab	13
Clinical recommendations on lung cancer management during the COVID‐19 pandemic	13
Ultrasound location of pulmonary nodules in video‐assisted thoracoscopic surgery for precise sublobectomy	12
Ultrathin bronchoscope combined with virtual bronchoscopic navigation and endobronchial ultrasound for the diagnosis of peripheral pulmonary lesions with or without fluoroscopy: A randomized trial	12
Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting:	12
Tumor invasion in the central airway is a risk factor for early‐onset checkpoint inhibitor pneumonitis in patients with non‐small cell lung cancer	12
Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1⁺CD8⁺ and CD8⁺ T cells as predictive of response to neoadjuvant chemotherapy i	12
HAX1 enhances the survival and metastasis of non‐small cell lung cancer through the AKT/mTOR and MDM2/p53 signaling pathway	12
Use of glucocorticoids in the management of immunotherapy‐related adverse effects	12
Prediction of tumor doubling time of lung adenocarcinoma using radiomic margin characteristics	12
Comparison of adequacy between transbronchial lung cryobiopsy samples and endobronchial ultrasound‐guided transbronchial needle aspiration samples for next‐generation sequencing analysis	12
Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients	12
MiR‐423‐5p aggravates lung adenocarcinoma via targeting CADM1	12
miR‐223‐3p targets FBXW7 to promote epithelial‐mesenchymal transition and metastasis in breast cancer	12
Progesterone/Org inhibits lung adenocarcinoma cell growth via membrane progesterone receptor alpha	12
The landscape of small cell lung cancer metastases: Organ specificity and timing	12
Lung cancer risk prediction models based on pulmonary nodules: A systematic review	12
Reproducible abscopal effect in a patient with lung cancer who underwent whole‐brain irradiation and atezolizumab administration	12
Performance of lung cancer screening with low‐dose CT in Gejiu, Yunnan: A population‐based, screening cohort study	12
Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer	12
Prognostic impact of micropapillary component in patients with node‐negative subcentimeter lung adenocarcinoma: A Chinese cohort study	12
Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab	12
MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer	12

Liquid biopsies to distinguish malignant from benign pulmonary nodules	12
Evaluation of dual‐energy and perfusion CT parameters for diagnosing solitary pulmonary nodules	11
High expression of KITLG is a new hallmark activating the MAPK pathway in type A and AB thymoma	11
Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study	11
Circ_0000520 contributes to triple‐negative breast cancer progression through mediating the miR‐1296/ZFX axis	11
M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR	11
Prognostic value of ferroptosis‐related genes in patients with lung adenocarcinoma	11
Opportunistic infections complicating immunotherapy for non‐small cell lung cancer	11
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report	11
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases	11
Microwave ablation via a flexible catheter for the treatment of nonsurgical peripheral lung cancer: A pilot study	11
MiR‐192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF‐κB pathway	11
Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non‐small cell lung cancer	11
Estimated direct costs of non‐small cell lung cancer by stage at diagnosis and disease management phase: A whole‐disease model	11
LncRNA SNHG14 contributes to the progression of NSCLC through miR‐206/G6PD pathway	11
Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness	11
Clinical characteristics and prognosis of pulmonary large cell carcinoma: A population‐based retrospective study using SEER data	11
Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Ja	11
Surgical outcomes of 215 patients with thymic epithelial tumors: A single‐center experience	11
ALK‐rearranged squamous cell carcinoma of the lung	11
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy	11
Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer	11
Construction of PEI‐EGFR‐PD‐L1‐siRNA dual functional nano‐vaccine and therapeutic efficacy evaluation for lung cancer	11
Circular RNA circCPA4 promotes tumorigenesis by regulating miR‐214‐3p/TGIF2 in lung cancer	11
Thymoma‐associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma	11
GRP75‐mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c‐JUN signaling	11
The LungVision navigational platform for peripheral lung nodule biopsy and the added value of cryobiopsy	11
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non‐small cell lung cancer (AB‐CLICaP)	11
Exosomal circDNER enhances paclitaxel resistance and tumorigenicity of lung cancer via targeting miR‐139‐5p/ITGB8	11
Matrix metalloproteinase‐14 (MMP‐14) downregulation inhibits esophageal squamous cell carcinoma cell migration, invasion, and proliferation	11
Oncological advantage of nonintubated thoracic surgery: Better compliance of adjuvant treatment after lung lobectomy	11
Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation	10
Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China	10
BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A	10
Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis	10
The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer	10
Remarkable response of non‐small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis	10
Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment	10
Mediastinal “deep freeze”—transcarinal lymph node cryobiopsy	10
Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events	10
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples	10
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis	10
Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutati	10
Interstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14	10
Effects of avitinib on the pharmacokinetics of osimertinib in vitro and in vivo in rats	10
Health‐related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ‐5D: A multicenter cross‐sectional study	10
Autologous blood pleurodesis for the treatment of postoperative air leaks. A systematic review and meta‐analysis	10
Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors	10
Circ_ZFR affects FABP7 expression to regulate breast cancer progression by acting as a sponge for miR‐223‐3p	10
Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network me	10
PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer	10
Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review	10
lncRNAs classifier to accurately predict the recurrence of thymic epithelial tumors	10
The airway microbiota of non‐small cell lung cancer patients and its relationship to tumor stage andEGFRgene mutation	10
Successful use of extracorporeal membrane oxygenation for airway‐obstructing lung adenocarcinoma	10
DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC	10
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer	10
Intraoperative diagnosis of lymph node metastasis during segmentectomy for non‐small cell lung cancer by rapid immunohistochemistry using noncontact alternating current electric field mixing	10
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC	10
Fresh fruit consumption may decrease the long‐term risk of esophageal cancer mortality: A 30‐year follow‐up study in the Linxian Dysplasia Nutrition Intervention trial (NIT)	10
TMEM107 inhibits EMT and invasion of NSCLC through regulating the Hedgehog pathway	10
Elevations of monocyte and neutrophils, and higher levels of granulocyte colony‐stimulating factor in peripheral blood in lung cancer patients	10
Management of chyle leakage after general thoracic surgery: Impact of thoracic duct embolization	9
Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer	9
Dynamics of D‐dimer in non‐small cell lung cancer patients receiving radical surgery and its association with postoperative venous thromboembolism	9
Clinical‐radiological characteristics and intestinal microbiota in patients with pancreatic immune‐related adverse events	9
Use of PD‐1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report	9
Surgical perspective in neoadjuvant chemoimmunotherapy for stage II–III non‐small cell lung cancer	9
Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non‐small‐cell lung cancer and ERBB2 mutation	9
A retrospective stenting study on superior vena cava syndrome caused by lung cancer	9
LncRNA SNHG20 promoted proliferation, invasion and inhibited cell apoptosis of lung adenocarcinoma via sponging miR‐342 and upregulating DDX49	9
Lung‐specific exosomes for co‐delivery of CD47 blockade and cisplatin for the treatment of non–small cell lung cancer	9
Chaperone‐mediated autophagy affects tumor cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma	9
Silencing LINC01116 suppresses the development of lung adenocarcinoma via the AKT signaling pathway	9
Outcomes of lobectomy on pulmonary function for early stage non‐small cell lung cancer (NSCLC) patients with chronic obstructive pulmonary disease (COPD)	9
Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis	9
Feasibility investigation of near‐infrared fluorescence imaging with intravenous indocyanine green method in uniport video‐assisted thoracoscopic anatomical segmentectomy for identifying the intersegm	9
Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report	9
Clinical characteristics and management of primary mediastinal cysts: A single‐center experience	9
Lung adenocarcinoma patients with KEAP1 mutation harboring low immune cell infiltration and low activity of immune environment	9
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma	9
Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival	9
Increased activation of cGAS‐STING pathway enhances radiosensitivity of non‐small cell lung cancer cells	9
Inflammation‐nutritional markers of peripheral blood could predict survival in advanced non‐small‐cell lung cancer patients treated with PD‐1 inhibitors	9
Preoperative predictors of restoration in quality of life after surgery for lung cancer	9
Remarkable response to pembrolizumab with platinum‐doublet in PD‐L1‐low pulmonary sarcomatoid carcinoma: A case report	9
Recombinant human adenovirus type 5 (Oncorine) reverses resistance to immune checkpoint inhibitor in a patient with recurrent non‐small cell lung cancer: A case report	9
Clinical evaluation of the effectiveness of fusion‐induced asymmetric transcription assay‐based reverse transcription droplet digital PCR for ALK detection in formalin‐fix	9
Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer	9
The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis	9
Susceptibility of lung cancer patients to COVID‐19: A review of the pandemic data from multiple nationalities	9
Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure	9
Radiation dose escalation with modified fractionation schedules for locally advanced NSCLC: A systematic review	9
Long non‐coding RNA CCAT1 sponges miR‐490 to enhance cell proliferation and migration of non‐small cell lung cancer	9
Quantitative analysis of endobronchial ultrasound elastography in computed tomography‐negative mediastinal and hilar lymph nodes	9